Printer Friendly

U.S. BIOSCIENCE OBTAINS RIGHTS TO SELL OVARIAN CANCER DRUG IN EUROPE AND ISRAEL

 U.S. BIOSCIENCE OBTAINS RIGHTS TO SELL OVARIAN CANCER
 DRUG IN EUROPE AND ISRAEL
 WEST CONSHOHOCKEN, Pa., March 18 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS), a company focused on the development and commercialization of new treatments for cancer and allied diseases, has acquired the exclusive right to use the regulatory registrations and approvals for sale held by Rhone-Poulenc Rorer for the compound altretamine in several European countries and Israel. Altretamine, an anti-cancer agent used in the treatment of ovarian cancer, is currently marketed by U.S. Bioscience in the United States under the trade name Hexalen(R).
 Rhone-Poulenc Rorer has regulatory approval to market altretamine, under the trade name Hexastat(R), in each of the five countries of the agreement: Germany, Italy, Holland, Israel and Czechoslovakia. U.S. Bioscience will be marketing altretamine in these countries under the trade name Hexalen(R).
 Philip S. Schein, M.D., chairman and chief executive officer of U.S. Bioscience, said, "We are pleased to conclude this agreement as it will serve as a base from which to build our commercial activities in Europe -- a significant market for our future growth as an international pharmaceutical company."
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life of patients with cancer and allied diseases.
 -0- 3/18/92
 /NOTE: An agreement in principle was announced Nov. 19, 1991./
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Charles Versaggi of Versaggi & Associates, 408-358-4162 or 408-395-1877, for U.S. Bioscience/
 (UBS) CO: U.S. Bioscience ST: California IN: MTC SU:


TS-RM -- SJ002 -- 9051 03/18/92 08:27 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:282
Previous Article:ABB'S U.S. RESULTS TURN AROUND IN 1991
Next Article:BURLINGTON DEBT TENDER OFFERS EXTENDED
Topics:


Related Articles
U.S. BIOSCIENCE GAINS EUROPEAN MARKETING RIGHTS TO OVARIAN CANCER DRUG
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
FDA PANEL WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL(R)
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
SCHERING-PLOUGH AND U.S. BIOSCIENCE
ODAC WITHHOLDS RECOMMENDATION TO APPROVE ETHYOL; U.S. BIOSCIENCE, INC. TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF ETHYOL
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES
ALZA CORP.: ETHYOL(R) RECEIVES ADDITIONAL INDICATION FOR USE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters